Last reviewed · How we verify
Fecal Microbiota Transplant with Pembrolizumab
Fecal microbiota transplant modulates the gut microbiome to stimulate an anti-tumor immune response through PD-1/PD-L1 pathway.
Fecal microbiota transplant modulates the gut microbiome to stimulate an anti-tumor immune response through PD-1/PD-L1 pathway. Used for Melanoma, Non-small cell lung cancer, Head and neck squamous cell carcinoma.
At a glance
| Generic name | Fecal Microbiota Transplant with Pembrolizumab |
|---|---|
| Sponsor | Zarour, Hassane, MD |
| Drug class | Immunotherapy |
| Target | PD-1/PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fecal microbiota transplant (FMT) involves transferring fecal matter from a healthy donor into a patient's gastrointestinal tract to restore a balanced gut microbiome. This can stimulate an anti-tumor immune response by increasing the expression of PD-L1 on tumor cells, thereby inhibiting the PD-1/PD-L1 pathway and enhancing T-cell activity against cancer cells.
Approved indications
- Melanoma
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC (PHASE2)
- Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma (PHASE2)
- Fecal Microbiota Transplant (FMT) in Melanoma Patients (PHASE2)
- Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy (NA)
- Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma (PHASE2)
- Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. (PHASE2)
- Gut Microbiota Reconstruction for NSCLC Immunotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: